Compare PEBO & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | NNNN |
|---|---|---|
| Founded | 1902 | 2021 |
| Country | United States | Germany |
| Employees | N/A | 27 |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2005 | N/A |
| Metric | PEBO | NNNN |
|---|---|---|
| Price | $34.90 | $33.59 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $37.33 | N/A |
| AVG Volume (30 Days) | ★ 144.9K | 14.9K |
| Earning Date | 04-21-2026 | 04-07-2026 |
| Dividend Yield | ★ 4.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $197,000.00 | N/A |
| Revenue This Year | $17.29 | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | ★ $42.93 | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.49 | $7.76 |
| 52 Week High | $35.46 | $55.65 |
| Indicator | PEBO | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 66.49 |
| Support Level | $33.56 | $26.31 |
| Resistance Level | $35.46 | $44.06 |
| Average True Range (ATR) | 0.60 | 3.05 |
| MACD | 0.09 | 0.66 |
| Stochastic Oscillator | 86.27 | 90.43 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).